Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Allakos Inc. - Common Stock (NQ: ALLK ) 1.260 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 1.260 Bid (Size) 0.9920 (4) Ask (Size) 1.350 (3) Prev. Close 1.260 Today's Range 1.260 - 1.260 52wk Range 0.5350 - 3.360 Shares Outstanding 86,560,315 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 10 Health Care Stocks Whale Activity In Today's Session November 05, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session October 24, 2024 Via Benzinga Performance YTD -54.01% -54.01% 1 Month +40.91% +40.91% 3 Month +118.94% +118.94% 6 Month +18.87% +18.87% 1 Year -54.01% -54.01% More News Read More 12 Health Care Stocks Moving In Wednesday's After-Market Session October 23, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session October 22, 2024 Via Benzinga ALLK Stock Earnings: Allakos Beats EPS for Q2 2024 August 07, 2024 Via InvestorPlace ALLK Stock Earnings: Allakos Meets EPS for Q1 2024 May 09, 2024 Via InvestorPlace ALLK Stock Earnings: Allakos Misses EPS for Q4 2023 March 14, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Friday's After-Market Session October 11, 2024 Via Benzinga Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers October 10, 2024 From Allakos Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Pre-Market Session October 04, 2024 Via Benzinga Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results August 07, 2024 From Allakos Inc. Via GlobeNewswire Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile June 25, 2024 From Allakos Inc. Via GlobeNewswire Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria May 28, 2024 From Allakos Inc. Via GlobeNewswire Allakos Provides Business Update and Reports First Quarter 2024 Financial Results May 09, 2024 From Allakos Inc. Via GlobeNewswire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 03, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Wednesday's After-Market Session May 01, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday April 15, 2024 Via InvestorPlace 3 Biotech Stocks to Dump Before They Go to Zero April 09, 2024 Via InvestorPlace Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results March 14, 2024 From Allakos Inc. Via GlobeNewswire Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024 February 26, 2024 From Allakos Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session February 14, 2024 Via Benzinga Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition February 12, 2024 From Allakos Inc. Via GlobeNewswire Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday January 17, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session January 17, 2024 Via Benzinga Gold Down 1%; PNC Financial Posts Upbeat Earnings January 16, 2024 Via Benzinga Topics Stocks Exposures US Equities Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
